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In 2007, the Wellcome Trust Case Control Consortium (WTCCC) performed a genome-wide association study in
2,000 British coronary heart disease (CHD) cases and 3,000 controls after genotyping 469,557 single nucleotide
polymorphisms (SNPs). Seven variants associated with CHD were initially identified, and 5 SNPs were later found
in replication studies. In the current study, the authors aimed to determine whether the 12 SNPs reported by the
WTCCC predicted incident CHD through 2004 in a biracial, prospective cohort study (Atherosclerosis Risk in
Communities) comprising 15,792 persons aged 45–64 years who had been selected by probability sampling from
4 different US communities in 1987–1989. Cox proportional hazards models with adjustment for age and gender
were used to estimate CHD hazard rate ratios (HRRs) over a 17-year period (1,362 cases in whites and 397 cases
in African Americans) under an additive genetic model. The results showed that 3 SNPs in whites (rs599839,
rs1333049, and rs501120; HRRs were 1.10 (P ¼ 0.044), 1.14 (P < 0.001), and 1.14 (P ¼ 0.030), respectively)
and 1 SNP in African Americans (rs7250581; HRR ¼ 1.60, P ¼ 0.05) were significantly associated with incident
CHD. This study demonstrates that genetic variants revealed in a case-control genome-wide association study
enriched for early disease onset may play a role in the genetic etiology of CHD in the general population.
coronary disease; genetic variation; genetics; genomics; heart diseases; myocardial infarction; polymorphism,
single nucleotide
Abbreviations: ARIC, Atherosclerosis Risk in Communities; CHD, coronary heart disease; HDL, high density lipoprotein; LDL, low
density lipoprotein; SDF-1, stromal cell-derived factor 1; SNP, single nucleotide polymorphism; WTCCC, Wellcome Trust Case
Control Consortium.
Editor’s note: An invited commentary on this article
appears on page 24.
Genetic studies designed to identify sequence variants
implicated in complex disorders have recently focused on
genome-wide association studies of the relations between
large numbers of single nucleotide polymorphisms (SNPs)
measured simultaneously and disease risk. The development
of high-density genotyping arrays and the availability of the
HapMap database (http://hapmap.ncbi.nlm.nih.gov/), which
describes common patterns of sequence variation in 4 differ-
ent populations (1), have facilitated this approach and enabled
the successful detection of SNPs that contribute to the etiol-
ogy of such common diseases as type 2 diabetes (2–7), obesity
(8–11), coronary heart disease (CHD) (2, 12, 13), and
Alzheimer’s disease (14, 15). In many of these studies, SNPs
in genes previously reported to be associated with the pheno-
type of interest, such as transcription factor 7-like 2 and type 2
diabetes (2–5, 16), as well as SNPs in genes or pathways not
previously known to be involved in disease pathogenesis,
were identified. The replicated association of the fat mass-
and obesity-associated gene with obesity is one such example
and demonstrates the utility of this approach (9–11).
The Wellcome Trust Case Control Consortium (WTCCC)
was formed in Great Britain to carry out an experiment in
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which approximately 2,000 cases for each of 7 complex
diseases and 3,000 shared controls were genotyped using
the Affymetrix GeneChip 500K Mapping Array Set (2).
Seven SNPs showing either strong (P < 5 3 107) or
moderate (P ¼ 105–107) association with CHD were
identified in a sample enriched for premature myocardial
infarction or coronary revascularization occurring before
the 66th birthday. A second report was subsequently pub-
lished by the same consortium that presented evidence for
replication in the German Myocardial Infarction Family
Study for 3 genetic variants, including 2 of the 7 most likely
susceptibility loci for CHD from the first report (17). Four
additional loci were then identified when a combined anal-
ysis of the data from the original WTCCC study and the
German Myocardial Infarction Family Study was under-
taken. All of the SNPs are located on separate chromosomes
or chromosomal regions, so they are not in linkage disequi-
librium with each other; information concerning putative
candidate genes in these regions and their function is pro-
vided in the Appendix Table. Our aim in the current study
was to determine whether any of the 12 SNPs found to
contribute to coronary artery disease susceptibility in the
WTCCC study were associated with incident CHD in
a large, biracial, population-based cohort.
MATERIALS AND METHODS
Study population
The Atherosclerosis Risk in Communities (ARIC) Study
is a prospective longitudinal investigation of the develop-
ment of atherosclerosis involving 15,792 persons aged
45–64 years who were selected by probability sampling
from 4 different communities in the United States. At the
time of recruitment in 1987–1989, the participants were
residents of Forsyth County, North Carolina; Jackson,
Mississippi (African Americans only); the northwestern
suburbs of Minneapolis, Minnesota; or Washington County,
Maryland. Participants in the ARIC Study were excluded
from analysis if they were African Americans from the
Minnesota or Maryland field center (n ¼ 48), because of
the small numbers recruited from these sites, or if they were
neither African-American nor white (n ¼ 43). Additional
exclusion criteria were: missing genotype data for all se-
quence variants (n ¼ 540); a positive or unknown history
of CHD, prevalent stroke, or a history of transient ischemic
attack at the initial clinic visit (n ¼ 1,446); and participant
refusal for the use of DNA (n ¼ 40). When these persons
were excluded, the study sample consisted of 13,675
participants.
The initial clinical examination, referred to herein as visit
1, was carried out in 1987–1989 and included an interview
designed to elicit information about the presence of cardio-
vascular disease risk factors, socioeconomic status, and fam-
ily medical history. Incidence of CHD was determined over
a period of 17 years by telephoning participants annually and
by surveying discharge lists from local hospitals and death
certificates from state vital statistics offices for potential car-
diovascular events (18). Incident CHD cases were defined as
those involving a definite or probable myocardial infarction,
a silent myocardial infarction between examinations deter-
mined by electrocardiography, a definite CHD death, or a
coronary revascularization procedure. Participants were fol-
lowed for a mean of 13.1 years. A total of 1,759 CHD cases
were identified through December 31, 2004.
All of the persons enrolled in the ARIC Study provided
written informed consent, and the study design and methods
were approved by institutional review boards at the collab-
orating medical centers. A detailed description of the ARIC
Study has been published previously (19).
Baseline clinical and laboratory measurements
The prevalence of diabetes at visit 1 was defined as a fast-
ing glucose level 126 mg/dL, a nonfasting glucose level
200 mg/dL, and/or self-reported physician diagnosis of or
treatment for diabetes. Body mass index (weight (kg)/height
(m)2) was calculated from height and weight measurements
obtained at the baseline examination. Seated blood pressure
was measured 3 times using a random-zero sphygmoma-
nometer, and the last 2 measurements were averaged. Hy-
pertension was defined as systolic blood pressure 140 mm
Hg or diastolic blood pressure 90 mm Hg or current use of
antihypertensive medication. Cigarette smoking status was
analyzed by comparing current smokers with persons who
had formerly or never smoked. Plasma total cholesterol
level was measured by an enzymatic method (20), and the
portion of low density lipoprotein (LDL) cholesterol was
calculated (21). The level of high density lipoprotein
(HDL) cholesterol was measured after dextran-magnesium
precipitation of non-HDL cholesterol (22).
Genotype determination
Genotyping of 12 SNPs previously identified either in the
genome-wide association study of coronary artery disease
carried out in the United Kingdom (2) or in the German
Myocardial Infarction Family Study (17) was performed
using the TaqMan assay (Applied Biosystems, Foster City,
California). The oligonucleotide sequences for polymerase
chain reaction primers and TaqMan probes are available
upon request from the authors. Allele detection was per-
formed using the ABI Prism 7700 Sequence Detection Sys-
tem (Applied Biosystems). The genotype call rate, or the
percentage of samples to which a genotype was assigned,
was determined prior to exclusion of individuals from the
analysis and ranged from 93.8% for rs2943634 to 94.8% for
rs688034. After the application of all exclusion criteria, the
proportion of missing genotype data in the final study sam-
ple did not exceed 2.4% for any of the genetic variants. We
also assessed the genotyping success rate by analyzing the
concordance between genotypes for pairs of blind dupli-
cates included with the DNA samples from the study par-
ticipants. Kappa coefficients (23), an index of the
percentage of agreement between measurements, corrected
for agreement occurring by chance, were calculated for each
SNP and ranged from 0.96 to 0.99.
Statistical analysis
Statistical analysis was carried out using the Stata statis-
tical software program, version 9.0 (Stata Corporation,
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College Station, Texas). The hypothesis that observed
genotypes were in Hardy-Weinberg equilibrium was tested
in noncases using a v2 goodness-of-fit test. The proportions,
mean values, and standard deviations were calculated for
established CHD risk factors for both the incident CHD
cases and the comparison group of persons who did not meet
the case definition. Cox proportional hazards models were
used to estimate hazard rate ratios for CHD. For analyses of
CHD cases, follow-up time intervals were defined as the
time between visit 1 and the date of the first CHD event.
For noncases, follow-up continued through one of the fol-
lowing dates: December 31, 2004, the date of death, or the
date of last contact if the participant was lost to follow-up.
Covariates were assessed for statistical significance in the
models using the Wald v2 statistic. The results of all statis-
tical analyses are presented separately by self-reported ra-
cial group. A 2-sided P value less than 0.05 was considered
statistically significant, with no correction applied for mul-
tiple comparisons, since there were strong prior odds of
association based on the results of the WTCCC case-control
studies (2, 17). Power analyses were conducted using the
Cox regression module of the Power Analysis and Sample
Size program (24).
RESULTS
Proportions, means, and standard deviations for the estab-
lished CHD risk factors are shown in Table 1. The mean
values for all clinical characteristics at visit 1 differed sig-
nificantly between participants who developed CHD and
noncases for both whites and African Americans, with the
exception of mean body mass index for African-American
participants. For both racial groups, CHD cases included
a higher frequency of males, persons affected by diabetes
and hypertension, and smokers in comparison with
noncases.
Genotype frequencies for the polymorphisms identified in
the WTCCC case-control study differed significantly in
noncases between whites and African Americans (data not
shown), so subsequent statistical analyses were performed
separately by race. The allele and genotype frequencies
for all genetic variants were in accordance with Hardy-
Weinberg equilibrium expectations for whites. One of the
12 SNPs did not meet Hardy-Weinberg expectations at a
P value of 0.05 for African Americans in the study sample
(rs7250581, P ¼ 0.01); this may be attributable to the low
minor allele frequency observed for this genetic variant.
Table 2 shows genotype frequencies for the WTCCC SNPs
in the ARIC cohort after stratification by race. There were
significant differences between incident CHD cases and
noncases for 3 of the SNPS in whites (rs1333049,
rs501120, and rs8055236).
Table 3 shows results from Cox proportional hazards
models used to estimate hazard rate ratios for incident
CHD, stratified by both SNP and racial group. An additive
genetic model was chosen for these analyses for consistency
with the WTCCC reports (2, 17), and all of the genotypes
for the individual SNPs were coded with respect to the risk
allele for coronary artery disease determined by the
WTCCC so that direction of effect could be easily com-
pared. After adjustment for age and gender (model 1),
rs7250581 was a nominally significant predictor of incident
CHD for African Americans (hazard rate ratio ¼ 1.60,
P ¼ 0.05), while 3 of the SNPS (rs599839, rs1333049,
and rs501120) were associated with incident CHD for
whites (hazard rate ratios were 1.10 (P ¼ 0.044), 1.14
(P < 0.001), and 1.14 (P ¼ 0.030), respectively). When




Cases (n 5 397)
Noncases
(n 5 3,206) P
Valuea
Incident CHD
Cases (n 5 1,362)
Noncases
(n 5 8,710) P
Valuea
No. or Mean % No. or Mean % No. or Mean % No. or Mean %
Age, years 54.8 (5.77)b 53.1 (5.78) <0.001 55.5 (5.48) 53.9 (5.71) <0.001
Body mass indexc 29.9 (5.71) 29.6 (6.15) 0.351 27.9 (4.67) 26.8 (4.84) <0.001
Cholesterol level, mmol/L
HDL cholesterol 1.27 (0.37) 1.45 (0.46) <0.001 1.11 (0.32) 1.35 (0.44) <0.001
LDL cholesterol 3.89 (1.23) 3.50 (1.08) <0.001 3.88 (0.98) 3.48 (0.96) <0.001
Total cholesterol 5.85 (1.32) 5.50 (1.14) <0.001 5.80 (1.07) 5.50 (1.04) <0.001
Male gender 197 49.6 1,131 35.3 <0.001 931 63.4 3,643 41.8 <0.001
Diabetes mellitus 125 32.0 523 16.6 <0.001 267 19.7 557 6.4 <0.001
Hypertension 285 71.8 1,662 52.1 <0.001 520 38.3 2,038 23.5 <0.001
Current smoking 160 40.5 893 27.9 <0.001 424 31.1 2,041 23.4 <0.001
Abbreviations: CHD, coronary heart disease; HDL, high density lipoprotein; LDL, low density lipoprotein.
a The significance of the difference between groupmean values was determined by t test; categorical variables were evaluated by Pearson’s chi-
squared test.
b Numbers in parentheses, standard deviation.
c Weight (kg)/height (m)2.
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ValuedNo. % No. % No. % No. %
rs599839 A/G 1p13 0.73 0.774 0.23 0.204
AA 33 8.5 236 7.6 821 61.7 5,062 59.2
AG 151 38.9 1,194 38.4 444 33.4 3,017 35.3
GG 204 52.6 1,676 54.0 65 4.9 469 5.5
rs17465637 C/A 1q14 0.75 0.881 0.28 0.595
CC 28 7.2 204 6.5 712 53.5 4,462 52.0
AC 142 36.5 1,152 36.9 519 39.0 3,457 40.3
AA 219 56.3 1,769 56.6 99 7.5 656 7.7
rs17672135 T/C 1q43 0.10 0.766 0.12 0.112
TT 308 80.2 2,550 81.4 1,051 78.2 6,609 76.8
CT 71 18.5 552 17.6 266 19.8 1,871 21.7
CC 5 1.3 31 1.0 27 2.0 128 1.5
rs2943634 C/A 2q36 0.59 0.883 0.34 0.361
CC 62 16.1 535 17.1 598 44.9 3,746 44.1
AC 187 48.6 1,500 48.0 596 44.8 3,764 44.3
AA 136 35.3 1,091 34.9 137 10.3 988 11.6
rs383830 T/A 5q21 0.37 0.167 0.20 0.671
TT 176 45.5 1,265 40.5 873 65.2 5,513 64.0
AT 160 41.3 1,412 45.2 410 30.6 2,742 31.8
AA 51 13.2 449 14.3 56 4.2 360 4.2
rs6922269 A/A 6q25 0.55 0.340 0.27 0.491
GG 68 17.4 637 20.3 717 53.4 4,569 53.2
AG 206 52.7 1,555 49.6 517 38.5 3,403 39.6
AA 117 29.9 944 30.1 108 8.1 621 7.2
rs1333049 C/C 9p21 0.23 0.384 0.47 0.007
GG 239 62.2 1,849 59.3 321 23.9 2,389 27.8
CG 120 31.3 1,083 34.8 687 51.1 4,276 49.7
CC 25 6.5 184 5.9 336 25.0 1,939 22.5
rs501120 T/C 10q11 0.41 0.606 0.13 0.042
TT 133 34.4 1,064 34.5 1,050 78.1 6,465 75.2
CT 196 50.8 1,505 48.8 277 20.6 1,977 23.0
CC 57 14.8 513 16.7 17 1.3 157 1.8
rs17228212 C/C 15q22 0.12 0.631 0.28 0.696
TT 304 77.2 2,414 77.4 684 50.7 4,446 51.7
CT 86 21.8 653 21.0 546 40.5 3,443 40.1
CC 4 1.0 50 1.6 118 8.8 704 8.2
rs8055236 G/T 16q23 0.54 0.985 0.19 0.002
GG 87 22.4 684 22.0 873 65.0 5,674 66.1
GT 189 48.6 1,522 49.0 399 29.7 2,630 30.6
TT 113 29.0 901 29.0 71 5.3 286 3.3
rs7250581 G/A 19q12 0.03 0.172 0.18 0.243
GG 374 95.9 2,922 93.6 920 68.7 5,717 66.6
AG 16 4.1 190 6.1 380 28.4 2,564 29.9
AA 0 0.0 8 0.3 39 2.9 301 3.5
rs688034 T/T 22q12 0.10 0.521 0.33 0.365
CC 317 81.9 2,547 81.3 624 46.5 3,891 45.1
CT 64 16.5 554 17.7 561 41.8 3,778 43.8
TT 6 1.6 31 1.0 157 11.7 952 11.1
Abbreviations: CHD, coronary heart disease; ID, identification; rs, reference SNP; SNP, single nucleotide polymorphism; WTCCC, Wellcome
Trust Case Control Consortium.
a WTCCC, 2007 (2).
b The National Center for Biotechnology Information’s SNP database (http://www.ncbi.nlm.nih.gov/SNP/).
c Frequency among noncases of the minor allele identified in the WTCCC study (2).
d Significance of the difference in genotype frequencies between incident CHD cases and noncases, evaluated by Pearson’s chi-squared test.
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further adjustments were made for a group of CHD risk
factors including body mass index, smoking, diabetes status,
hypertension status, and HDL and LDL cholesterol levels
(model 2), the associations with rs7250581 for African
Americans and rs599839 for whites were no longer de-
tected. Since rs599839 was reported to be significantly as-
sociated with serum LDL cholesterol concentration in 2
genome-wide association studies conducted in European
Caucasian populations (25, 26), a third model incorporating
only age, gender, and LDL cholesterol was fitted, and the
association with incident CHD was eliminated (hazard rate
ratio ¼ 1.03, 95% confidence interval: 0.94, 1.13; P ¼
0.556). In addition, if the results of the comparison of ge-
notype frequencies between cases and noncases for each
genetic variant are also considered in the evaluation of the
effect of adjustment for covariates (Table 2), only rs1333049
and rs501120 are consistently associated with coronary ar-
tery disease case status in whites in all analyses. For
rs7250581 in African Americans, the further addition of ei-
ther body mass index, smoking, diabetes status, or hyperten-
sion status to the model adjusted for age and gender resulted
in the absence of a significant association with incident
CHD, while the inclusion of either LDL or HDL cholesterol
did not affect the observed relation (data not shown).
DISCUSSION
Coronary artery disease and its clinical sequelae, includ-
ing myocardial infarction, together constitute the single
greatest cause of death worldwide (27, 28). CHD has a com-
plex etiology, with multiple genes and environmental factors
believed to be involved in its pathogenesis. Although the
heritability of CHD is estimated to be 40%–60% (29), with
a risk to first-degree relatives that is 5–7 times higher than
that for members of the general population (30), the repro-
ducible identification of genetic variants underlying this
increased susceptibility has been difficult.
A genome-wide association study conducted by the
WTCCC compared the frequency of 469,557 SNPs in ap-
proximately 2,000 cases and 3,000 shared controls for 7
different complex diseases, including CHD (2). The CHD
cases in the WTCCC study included only persons with pre-
mature cardiovascular events occurring before the age of 66
years, to maximize the likelihood of detecting a genetic
component contributing to disease causation. Seven novel
variants were identified, with the strongest association being
found for an SNP (rs1333049) located in the same region of
chromosome 9p21 that was independently reported to har-
bor polymorphisms conferring increased risk of myocardial
infarction in 5 different Caucasian populations (12, 13).
However, the ascertainment scheme chosen by the WTCCC
may also have resulted in the choice of CHD cases that were
not representative of the population from which they were
drawn; thus, SNPs identified using this type of study design
may not be associated with CHD outside of the selected
subgroup. Our aim in the current investigation was to de-
termine whether any of the 7 SNPs associated with CHD
in the initial case-control study (2) and the 5 additional


















rs599839 1.06 0.91, 1.24 0.425 1.07 0.91, 1.25 0.397 1.10 1.00, 1.21 0.044 1.02 0.93, 1.12 0.684
rs17465637 1.02 0.87, 1.19 0.845 1.01 0.85, 1.19 0.942 1.04 0.95, 1.13 0.421 1.04 0.95, 1.13 0.439
rs17672135 0.90 0.72, 1.14 0.395 0.89 0.70, 1.14 0.361 1.06 0.94, 1.19 0.333 1.05 0.93, 1.19 0.405
rs2943634 0.98 0.85, 1.13 0.797 1.00 0.86, 1.15 0.954 1.05 0.97, 1.14 0.243 1.02 0.94, 1.11 0.553
rs383830 1.11 0.96, 1.28 0.166 1.06 0.91, 1.23 0.431 1.05 0.95, 1.15 0.344 1.03 0.94, 1.14 0.493
rs6922269 1.04 0.90, 1.19 0.587 1.05 0.90, 1.21 0.537 1.03 0.95, 1.12 0.487 1.01 0.93, 1.11 0.734
rs1333049 0.93 0.79, 1.11 0.426 0.92 0.77, 1.10 0.372 1.14 1.06, 1.24 <0.001 1.17 1.08, 1.26 <0.001
rs501120 1.07 0.92, 1.24 0.380 1.08 0.92, 1.25 0.342 1.14 1.01, 1.28 0.030 1.18 1.05, 1.33 0.006
rs17228212 0.96 0.78, 1.20 0.746 0.96 0.77, 1.19 0.723 1.05 0.96, 1.14 0.283 1.03 0.94, 1.12 0.512
rs8055236 1.00 0.87, 1.15 0.992 1.02 0.88, 1.18 0.790 0.92 0.84, 1.01 0.096 0.94 0.85, 1.03 0.201
rs7250581 1.60 0.99, 2.59 0.054 1.39 0.84, 2.31 0.204 1.07 0.97, 1.19 0.167 1.05 0.95, 1.16 0.361
rs688034 0.99 0.78, 1.25 0.921 0.98 0.78, 1.25 0.904 0.96 0.89, 1.04 0.351 0.94 0.86, 1.02 0.131
Abbreviations: CI, confidence interval; HRR, hazard rate ratio; ID, identification; rs, reference SNP; SNP, single nucleotide polymorphism.
a The National Center for Biotechnology Information’s SNP database (http://www.ncbi.nlm.nih.gov/SNP/).
b Results were adjusted for age and gender.
c Results were adjusted for age, gender, body mass index, smoking, diabetes case status, hypertension case status, high density lipoprotein
cholesterol, and low density lipoprotein cholesterol.
d Analysis was performed using an additive genetic model, coded with respect to the risk allele identified by the Wellcome Trust Case Control
Consortium (2).
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SNPs identified in replication studies conducted by the
WTCCC (17) predicted incident CHD in the large, biracial,
population-based ARIC cohort.
Two of the sequence variants described by the WTCCC in
case-control studies (rs1333049 and rs501120) were signif-
icantly associated with incident CHD for white participants
in the ARIC Study. Results from the Cox proportional haz-
ards models used to estimate the risk of CHD showed that
the 2 intergenic SNPs were independently associated with
CHD even after adjustment for multiple risk factors. One of
these SNPs (rs1333049) maps to a region of chromosome
9p21 previously reported to be associated with risk of myo-
cardial infarction among whites in the ARIC cohort (12).
The 58-kilobase genomic interval defining the risk allele
is located near the cyclin-dependent kinase inhibitor 2A,
cyclin-dependent kinase inhibitor 2B, and cyclin-dependent
kinase inhibitor antisense RNA loci, while there are no
annotated genes or micro-RNAs within the region itself
(Appendix Table).
The rs501120 variant is located approximately 127
kilobases downstream of the gene encoding stromal cell-
derived factor 1 (SDF-1) on chromosome 10q11. SDF-1 is
a member of the family of chemoattractant cytokines
known as chemokines and is the ligand for cell-surface
chemokine receptor 4. SDF-1 has been implicated in a wide
variety of biologic processes, including trafficking of he-
matopoietic stem and progenitor cells (31), migration of
lymphocytes and monocytes (32), and the recruitment of
endothelial progenitor cells derived from bone marrow to
ischemic tissues in animal models (33, 34). SDF-1 has also
been reported to be involved in the induction of platelet
aggregation, with high expression in smooth muscle cells,
endothelial cells, and macrophages in human atheroscle-
rotic plaques (35). Although the latter function suggests
that the rs501120 T allele could confer susceptibility to
CHD by playing a role in the regulation of thrombus for-
mation after plaque rupture, this would require rs501120 to
exert its effect at a considerable distance from the SDF-1
coding region (Appendix Table).
One additional SNP (rs599839) was associated with in-
cident CHD in whites when the results were adjusted only
for age and gender, but this relation was abolished after
either LDL or HDL cholesterol was added as an additional
covariate (P ¼ 0.556 and P ¼ 0.109, respectively). Since
the rs599839 polymorphism was recently reported to be
significantly associated with serum LDL cholesterol con-
centration in 2 genome-wide association studies conducted
in European Caucasian populations (25, 26), these results
suggest that the influence of this SNP on CHD risk in the
ARIC cohort may operate through its effect on plasma lipid
levels. The noncoding rs599839 variant is located near 3
coding genes on chromosome 1p13, including sortilin,
which is involved in the receptor-mediated binding of lipo-
protein lipase on the surface of adipocytes (36). A second
SNP that is in linkage disequilibrium with rs599839
(rs646776; r2 ¼ 0.89 in HapMap Utah residents with North-
ern and Western European ancestry) has been shown to be
correlated with the expression of sortilin in human liver cells
(25), providing a possible link to known events in lipopro-
tein metabolism (Appendix Table).
When incident CHD was examined in African Americans,
one of the 12 SNPs (rs7250581) showed a nominally signif-
icant relation after adjustment for age and gender that was
abrogated after the addition of multiple covariates known to
be associated with cardiovascular disease. However, since
the observed genotype frequencies for this variant did not
meet Hardy-Weinberg equilibrium expectations, the possi-
bility of a false-positive association must also be considered.
As Table 4 shows, there was 80% power to detect a hazard
rate ratio of 1.2–1.3 for 8 of the polymorphisms studied in
African Americans, and a hazard rate ratio of 1.1–1.2 could
be detected for all of the genetic variants in whites. There-
fore, the failure to identify significant associations between
most of the SNPs described in a population of Northern
European origin in the WTCCC case-control study and
Table 4. Cox Regression Hazard Rate Ratios for Incident Coronary
Heart Disease That Were Detectable at 80% Power, by Race,









b HRR b HRR
Model 1b rs599839 0.2216 1.248 0.1272 1.136
Model 2c rs599839 0.2220 1.249 0.1280 1.137
Model 1 rs17465637 0.2274 1.255 0.1201 1.128
Model 2 rs17465637 0.2278 1.256 0.1202 1.128
Model 1 rs17672135 0.3322 1.394 0.1632 1.177
Model 2 rs17672135 0.3326 1.395 0.1632 1.177
Model 1 rs2943634 0.2014 1.223 0.1133 1.120
Model 2 rs2943634 0.2016 1.223 0.1133 1.120
Model 1 rs383830 0.2027 1.225 0.1335 1.143
Model 2 rs383830 0.2030 1.225 0.1335 1.143
Model 1 rs6922269 0.2007 1.222 0.1208 1.128
Model 2 rs6922269 0.2010 1.223 0.1208 1.128
Model 1 rs1333049 0.2320 1.261 0.1074 1.113
Model 2 rs1333049 0.2323 1.261 0.1075 1.113
Model 1 rs501120 0.2036 1.226 0.1589 1.172
Model 2 rs501120 0.2039 1.226 0.1590 1.172
Model 1 rs17228212 0.3040 1.355 0.1184 1.126
Model 2 rs17228212 0.3042 1.356 0.1185 1.126
Model 1 rs8055236 0.1977 1.219 0.1371 1.147
Model 2 rs8055236 0.1979 1.219 0.1371 1.147
Model 1 rs7250581 0.5567 1.745 0.1385 1.149
Model 2 rs7250581 0.5581 1.747 0.1386 1.149
Model 1 rs688034 0.3322 1.394 0.1135 1.120
Model 2 rs688034 0.3326 1.395 0.1135 1.120
Abbreviations: HRR, hazard rate ratio; ID, identification; rs, refer-
ence SNP; SNP, single nucleotide polymorphism.
a The National Center for Biotechnology Information’s SNP data-
base (http://www.ncbi.nlm.nih.gov/SNP/).
b Results were adjusted for age and gender.
c Results were adjusted for age, gender, body mass index, smok-
ing, diabetes case status, hypertension case status, high density li-
poprotein cholesterol, and low density lipoprotein cholesterol.
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incident CHD in African Americans could be due to differ-
ences in linkage disequilibrium in the genomic regions
where the respective genetic markers reside; the SNPs iden-
tified by the WTCCC may be correlated with a true causa-
tive variant in whites but not in populations of African
origin. Another possibility is that there may be variation
in additional, as-yet-unknown genetic or environmental
factors that might modify the effect of the risk variants,
although this would need to be examined in a larger pop-
ulation of sufficient size to allow detection of such gene-
environment or gene-gene interactions (37). Alternatively,
the SNPs identified by the WTCCC were associated with
prevalent CHD case status, so for both white and African-
American participants, at least some of the polymorphisms
analyzed here might play a role in CHD only after it has
become well-established rather than in earlier events in
disease pathogenesis.
The odds ratios of 1.2 found for the 2 SNPs showing a sig-
nificant association with CHD in whites under an additive
genetic model were in accordance with the modest effects
reported for most common sequence variants influencing
complex disease in genome-wide association studies (38).
However, homozygous carriers of the susceptibility alleles
for the rs1333049 and rs501120 variants comprised 22.5%
and 75.2% of white persons in the ARIC cohort, respectively,
so the public health impact of these polymorphisms could be
substantial, and further investigation in other community-
based cohorts is warranted. Neither the WTCCC case-control
studies nor this study was designed to test alternative hypoth-
eses of disease causation (such as the contribution of copy
number variation or of rare variants with large effects) that
might help to further explain the observation that family
history of CHD is a strong predictor of disease risk.
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rs599839 1p21 CELSR2 604265 Knockdown in rat pups resulted in abnormal dendritic arborization 39, 40 29,515
1p13.3 PSRC1 Down-regulated by p53 and DNA damage 41 3#-UTR
1p21.3–p13.1 SORT1 602458 Sorting protein in rat adipocyte vesicles transporting SLC2A4 to
plasma membrane in response to insulin; binds LPL in adipocytes
36, 42, 43 118,407
rs17465637 1q41 MIA3 Extracellular protein broadly expressed in human tissues; tumor
suppressor in melanoma cell lines
44, 45 Intronic




rs383830 5q21.1 FAM174A Hypothetical protein 77,848
rs6922269 6q25.1 MTHFD1L 611427 MTHFD1L catalyzes tetrahydrofolate synthesis in mitochondria;
involved in de novo synthesis of purines and regeneration of
methionine from homocysteine; homocysteine identified as a risk
factor for vascular disease
48–50 Intronic
rs1333049 9p21 CDKN2A/CDKN2B 600160 CDKN2A encodes 2 proteins: p16(INK4), a cyclin-dependent
kinase inhibitor, and p14(ARF), involved in p53 regulation;
CDKN2B is an effector of TGFB-mediated cell cycle arrest
51, 52 150,455
600431 116,181
CDKN2BAS Noncoding RNA 53 130,703
rs501120 10q11.1 CXCL12 600835 Involved in platelet aggregation and expressed in macrophages
in human atherosclerotic plaques
35 126,685
rs17228212 15q22.33 SMAD3 603109 Transcriptional modulator activated by TGFB; Smad3 (/) mice
show enhanced intimal hyperplasia after vascular injury; SMAD3
expression detected in human atherosclerotic lesions and
restenotic plaques
54–56 Intronic
rs8055236 16q24.2–q24.3 CDH13 601364 Receptor for adiponectin; associated with adiponectin levels and
blood pressure; expressed in endothelial and smooth muscle
cells, atherosclerotic lesions, and restensotic plaques; inhibits
attachment of human aortic smooth muscle cells and endothelial
cells in culture
57–60 Intronic
rs7250581 19q12 POP4 606114 Subunit of human ribonuclease P; associated with RMRP, which is
involved in pre-rRNA processing
61, 62 32,815
rs688034 22q12.1 SEZ6L 607021 Associated with lung cancer 63, 64 Intronic
Abbreviations: CDH13, cadherin 13, H-cadherin (heart); CDKN2A, cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); CDKN2B, cyclin-dependent kinase inhibitor 2B
(p15, inhibits CDK4); CDKN2BAS, CDKN2B antisense RNA (non-protein-coding); CELSR2, cadherin, EGF LAG 7-pass G-type receptor 2 (flamingo homolog, Drosophila); CXCL12, chemo-
kine (C-X-C motif) ligand 12 (stromal cell-derived factor 1); FAM174A, family with sequence similarity 174, member A; FMN2, formin 2; ID, identification; LPL, lipoprotein lipase; MIA3,
melanoma inhibitory activity family, member 3;MTHFD1L, methylenetetrahydrofolate dehydrogenase (NADPþ-dependent) 1-like; OMIM, Online Mendelian Inheritance in Man; p53, transformation-
related protein 53; POP4, processing of precursor 4, ribonuclease P/MRP subunit (Saccharomyces cerevisiae); PSRC1, proline/serine-rich coiled-coil 1; RMRP, RNA component of mitochondrial
RNA processing endoribonuclease; rs, reference SNP; SEZ6L, seizure-related 6 homolog (mouse)-like; SLC2A4, solute carrier family 2 (facilitated glucose transporter), member 4; SMAD3, SMAD
family member 3; SNP, single nucleotide polymorphism; SORT1, sortilin 1; TGFB, transforming growth factor b1; UTR, untranslated region.
a Wellcome Trust Case Control Consortium, 2007 (2).
b The National Center for Biotechnology Information’s SNP database (http://www.ncbi.nlm.nih.gov/SNP/).
c McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, Maryland) and National Center for Biotechnology Information, National Library of Medicine
(Bethesda, Maryland) (http://www.ncbi.nlm.nih.gov/omim/).
d Genomic distance from the SNP (calculated using HapMap Data Release 27, February 2009 (1)).
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